Results 51 to 60 of about 2,408 (165)
International Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel +21 more
wiley +1 more source
IJU Case Reports, Volume 9, Issue 3, May 2026.ABSTRACT Introduction Nivolumab plus ipilimumab is a standard first‐line regimen for advanced renal cell carcinoma; however, primary tumors often respond less favorably to this combination than to immune checkpoint inhibitor–tyrosine kinase inhibitor regimens, and pathological complete response is rare.
Takuto Tsuchiya +9 more
wiley +1 more source
Urology Case Reports, 2020 We herein report a case involving a 59-year-old man with right lung and mediastinal lymph node metastases from renal cell carcinoma. After cytoreductive nephrectomy without neoadjuvant therapy, he achieved spontaneous regression.
Kuniyasu Muraoka +2 more
doaj +1 more source
Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
Indian Journal of Urology, 2015 Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy.
Mohammed Shahait +2 more
doaj +1 more source
Journal of Surgical Oncology, Volume 133, Issue 4, Page 421-432, March 15, 2026.ABSTRACT Background and Objective Palliative surgery in oncology aims to relieve symptoms, improve quality of life, and respect patient autonomy in advanced cancer. This study aimed to develop evidence‐based recommendations for safely indicating and performing palliative surgeries in Brazil, considering clinical, ethical, and multidisciplinary aspects.
Audrey Cabral Ferreira de Oliveira +15 more
wiley +1 more source
Renal cell carcinoma: An update for the practicing urologist
Asian Journal of Urology, 2015 Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to
Sumanta K. Pal +2 more
doaj +1 more source
Med Research, Volume 2, Issue 1, Page 89-105, March 2026.Preoperative VEGFR‐TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment remodeling. These immunologic changes improve the feasibility of 3D reconstruction‐guided robotic cytoreductive nephron‐sparing surgery, resulting in reduced
Wenhao Xu +10 more
wiley +1 more source
Long‐term outcomes after cytoreductive partial nephrectomy for metastatic renal cell carcinoma
BJUI Compass, Volume 7, Issue 1, January 2026.Abstract Objectives To assess treatment outcomes and evaluate patient selection criteria for cytoreductive partial nephrectomy (CRPN) in a unique cohort of metastatic renal cell carcinoma (mRCC) patients. Methods A retrospective review of mRCC patients who underwent CRPN between 1995 and 2023 at a single institution was performed.
Andrea Lopez Sanmiguel +9 more
wiley +1 more source
Clinical Interventions in Aging, 2020 Jiabi Chen, Qingliu He, Weihui Liu, Yining Li, Wei Zhuang Department of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, People’s Republic of ChinaCorrespondence: Wei ZhuangThe Second Affiliated Hospital of ...
Chen J, He Q, Liu W, Li Y, Zhuang W
doaj
Real‐world drivers of treatment choices in synchronous metastatic renal cell carcinoma
BJUI Compass, Volume 7, Issue 1, January 2026.Abstract Objectives This study aimed to identify clinical and socioeconomic factors associated with treatment selection and survival in patients diagnosed with synchronous metastatic renal cell carcinoma (mRCC). Patients and Methods The Renal Cell Cancer Database Sweden (RCCBaSe2.0), linking the National Swedish Kidney Cancer Register with other ...
Tarik Almdalal +4 more
wiley +1 more source